Posted: 19 September 2023
Australian Contract Research Organization (CRO) Mobius Medical Expands Global Footprint, Enters United States Market, with a Strategic Focus on Medical Devices.
Minneapolis, September 18, 2023 – In a strategic move to enhance its worldwide presence and bring its cutting-edge clinical trials management services to the United States, Mobius Medical, a leading Contract Research Organisation (CRO) in Australia and New Zealand, has officially entered the U.S. market. Leveraging its extensive expertise and track record in providing comprehensive solutions to the medical device, pharmaceutical, and biotechnology industries, Mobius Medical USA, Inc. aims to contribute to advancements in healthcare and innovation on American soil.
The company’s expansion into the United States will focus on collaborating with U.S. MedTech and pharmaceutical companies, innovation incubators, academic institutions, healthcare organizations, and the Medical Alley Association (MAA) to accelerate the development of new therapies and technologies.
“With over 15 years’ experience in clinical research, entering the United States market is a significant milestone for Mobius Medical,” said Stefan Czyniewski, CEO of Mobius Medical USA Inc. “We are excited to bring our expertise and capabilities to the forefront of therapeutic goods research in the U.S. Our goal is to continue to utilize the many advantages of conducting early-phase research in Australia (and New Zealand) and continue the clinical development plans with our clients in the U.S. We aim to deliver high-quality clinical trials and assist our clients to innovate and drive advancements that ultimately improve patient outcomes and contribute to the betterment of global healthcare. We are very pleased to welcome two key assets to the Mobius Family, Christian Carello, Head of Strategic Growth & Business Development and David Pomfret, VP of Clinical Operations, USA”.
Mobius Medical’s reputation for delivering high-quality clinical research in Australia has garnered it recognition across the industry. The company’s services encompass a wide range of disciplines, including clinical trials strategic advice, clinical trials management, data management, and bio-analytics. By establishing a presence in the United States, Mobius Medical aims to establish strategic collaborations that will propel the development of breakthrough therapies enabling them to reach patients sooner.
The U.S. expansion aligns with Mobius Medical’s overarching mission to accelerate the pace of scientific discovery and facilitate the translation of research findings into tangible solutions. The company’s multidisciplinary teams, and dedication to adherence to global regulatory standards make it an attractive partner for organizations seeking to advance their research and development efforts.
As Mobius Medical sets its sights on the American market, it remains steadfast in its commitment to upholding the highest standards of ethical research, scientific integrity, and collaboration. The company’s entrance into the United States represents a two-fold opportunity for our partners. Firstly, to continue to support early phase research in Australia, benefiting from its expeditious regulatory pathways and R&D tax incentives, and enjoy the continuity of our partnership in ongoing, future clinical trials in the U.S. Secondly, Mobius Medical USA, Inc. will be positioned to assist companies wishing to conduct their entire clinical programs on U.S. soil, with the regulatory expertise to seamlessly roll out the entire clinical program.
About Mobius Medical
Mobius Medical is a leading Contract Research Organisation (CRO) renowned for its comprehensive clinical trials management services in the medical device, pharmaceutical, and biotechnology sectors. With a history of driving innovation and a commitment to excellence, Mobius Medical partners with global clients to accelerate the development of life-changing therapies and technologies.